CorMedix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CorMedix and other ETFs, options, and stocks.

About CRMD

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. 

CEO
Joseph Todisco
CEOJoseph Todisco
Employees
65
Employees65
Headquarters
Berkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
2006
Founded2006
Employees
65
Employees65

CRMD Key Statistics

Market cap
893.47M
Market cap893.47M
Price-Earnings ratio
5.60
Price-Earnings ratio5.60
Dividend yield
Dividend yield
Average volume
3.20M
Average volume3.20M
High today
$11.79
High today$11.79
Low today
$11.04
Low today$11.04
Open price
$11.54
Open price$11.54
Volume
3.24M
Volume3.24M
52 Week high
$17.43
52 Week high$17.43
52 Week low
$5.60
52 Week low$5.60

Stock Snapshot

As of today, CorMedix(CRMD) shares are valued at $11.44. The company's market cap stands at 893.47M, with a P/E ratio of 5.60.

On 2025-12-16, CorMedix(CRMD) stock traded between a low of $11.04 and a high of $11.79. Shares are currently priced at $11.44, which is +3.6% above the low and -3.0% below the high.

The CorMedix(CRMD)'s current trading volume is 3.24M, compared to an average daily volume of 3.2M.

During the past year, CorMedix(CRMD) stock moved between $5.60 at its lowest and $17.43 at its peak.

During the past year, CorMedix(CRMD) stock moved between $5.60 at its lowest and $17.43 at its peak.

CRMD News

TipRanks 4d
Cormedix Director Makes a Significant Stock Sale!

New insider activity at Cormedix ( (CRMD) ) has taken place on December 11, 2025. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund le...

Simply Wall St 4d
Does CorMedix’s Insider Sale After a Strong Quarter Clarify or Complicate Its Growth Story?

On 9 December 2025, CorMedix director Steven W. Lefkowitz sold 40,000 shares of common stock for about US$475,200, leaving him with 80,498 shares, shortly after...

Does CorMedix’s Insider Sale After a Strong Quarter Clarify or Complicate Its Growth Story?
Nasdaq 5d
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

Shares of CorMedix CRMD have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy,...

CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

Analyst ratings

100%

of 7 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CRMD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.